Trials / Terminated
TerminatedNCT02057874
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC)
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to conventional imaging, multi-parametric 3-Tesla MRI offers the ability to quantitatively measure tissue structural, functional, cellular, and molecular properties, providing a more robust, clinically relevant method for assessing cancer response to therapy.
Conditions
- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Localized Resectable Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Stage A Adult Primary Liver Cancer (BCLC)
- Stage B Adult Primary Liver Cancer (BCLC)
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | 3 Tesla Magnetic Resonance Imaging | 3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered. |
| DRUG | Magnevist® (Intravenous (IV) administration of MRI contrast agent) | For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-11-19
- Completion
- 2015-12-04
- First posted
- 2014-02-07
- Last updated
- 2018-07-11
- Results posted
- 2018-07-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02057874. Inclusion in this directory is not an endorsement.